US appeals court revives Regeneron’s antitrust lawsuit against Novartis
2/2
FILE PHOTO: A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/FILE PHOTO
2/2
NOVN
-0.12%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
REGN
+0.29%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
NEW YORK (Reuters) – A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron (NASDAQ:REGN) Pharmaceuticals against Novartis (SIX:NOVN) related to prescription treatments to address a condition that can lead to eye disorders including permanent blindness.
The 2nd U.S. Circuit Court of Appeals in Manhattan said a lower court judge erred in dismissing the case, in part for having applied an improper legal standard to Regeneron’s claims.
